Mark Lubkeman

Mark Lubkeman has 30 years’ consulting experience with a focus on the health care industry, and until recently led BCG's Global Biopharma business as well as BCG's cross-industry Global Sales and Channels Effectiveness business. He has deep experience in working with CEOs, Boards, and senior management teams at companies in North America, Europe and Asia to transform to achieve competitive advantage, and build winning corporate and commercial strategies, capabilities, and organizations. Some of his relevant client work includes:- Leading eight biopharma company-wide transformation/restructuring efforts, with a particular focus on enhancing capabilities to grow, compete and win while reducing low value-adding activities and costs. One recent effort enhanced enterprise value by $20B.- Leading 22 major global pharma and medical device merger integration/divestitures, including the largest biotech and largest pharma mergers to date – for total deal value of more than $475B. Was often involved in the strategic due diligence of targets.- Leading or supporting several global product launches (strategy and/or execution), including the most successful pharma launch of all time, with $10B in first-year revenues.- Across a number of industries, analyzing/defining optimal corporate / BU strategy and commercial arrangements (market assessments, go-to-market models, sales and marketing effectiveness, required capabilities, organization, process, staffing, etc.), as well as several strategic planning efforts, generally focused on accelerating growth.- Supporting a range of CEO succession efforts for Boards and CEOs, ranging from transition design, selection, expertise development/onboarding, and CEO/candidate coaching pre/post successionBefore joining BCG, Mark was a Captain in U.S. Army Military Intelligence. He has a BA in Economics from Harvard University, and an MBA from the Harvard Graduate School of Business. He is fluent in Spanish and conversational in Dutch, French and German.